Mr. Lawrence is a partner and head of the firm's Pennsylvania Office.
He represents institutions and individuals, ranging from Fortune 100 companies to small businesses to individuals, in a range of complex litigation matters, focusing on healthcare recovery, investor representation and consumer protection litigation.
In 2014, Mr. Lawrence was again recognized, for a seventh time, as one of the "Top 100 Lawyers in Pennsylvania” and as one of the “Top 100 Lawyers in Philadelphia” in a survey of lawyers and judges published in Philadelphia Magazine, and previously published in the Philadelphia Inquirer. In 2013, Mr. Lawrence appeared in the National Law Journal supplement "Legal Leaders: Top Rated Lawyers in Pennsylvania". In addition, he has been recognized as a “Pennsylvania Super Lawyer” every year since 2005, and was selected in September 2006 by American Lawyer Media, The Pennsylvania Lawyer, and the Legal Intelligencer as one of their 45 Lawyers on the Fast Track.
Also in 2013, he was selected by American Lawyer Media as “one of New York's Top Rated Lawyers” as published in the New York Law Journal and New York Magazine.
Mr. Lawrence is the General Counsel of the Pennsylvania Democratic Party, and has a long history of political and community involvement. He has been thrice named as a Delegate to the Democratic National Convention, including by President Obama in 2012, and is Caucus Chairman of the Pennsylvania Democratic State Committee.
In April of 2014, the Supreme Court of Pennsylvania appointed Mr. Lawrence to the Board of Law Examiners. The seven member Board of lawyers and judges regularly meets to review bar admission rules and recommend specific rule changes, review proposed bar examination questions and analyses, approve examination results, set policy and handle all other bar admission obligations as charged by the Court. The Board holds formal hearings for applicants appealing the initial denial of their application to determine whether or not they meet the requirements for admission to the bar.
In addition, he served two terms, including as the Vice-Chairman, on the Disciplinary Board of the Supreme Court of Pennsylvania which regulates the conduct of Pennsylvania’s 75,000 licensed attorneys. Mr. Lawrence serves as Commissioner of Elections and Commissioner of Voter Registration of Delaware County, Pennsylvania, and previously served as an appointed Member of the Pennsylvania Securities Commission's Attorney Advisory Committee, and on the Investment Advisory Board of the Pennsylvania Supreme Court.
Mr. Lawrence is President of the James A. Finnegan Fellowship Foundation, which provides scholarships, stipends and internships to Pennsylvania students who express an interest in state government. Mr. Lawrence served as a member of the Finance Committee of the Board of Trustees of the Agnes Irwin School in Rosemont, Pennsylvania. In addition, he serves as an Alumni Interviewer for Georgetown University.
He has enjoyed success in a wide variety of cases.
Mr. Lawrence has represented health benefits plan providers and recovered hundreds of millions of dollars on their behalf, including in In re: Skelaxin (Metaxalone) Antitrust Litigation, Case No. 12-md-02343, MDL No. 2343 (D. Tenn.)(TPP allocation counsel), Blue Cross and Blue Shield Association, et al. v. SmithKlineBeecham Corp., Phila. C.C.P., August Term 2012, No. 997 (Flonase opt-out settlement), New England Carpenters Health Benefit Fund, et al. v. First DataBank, Inc. and McKesson Corp., No. 05-cv- 11148 (D. Ma.) (TPP allocation counsel for $285 million TPP share of $350 million settlement), Medical Mutual of Ohio v. Merck & Co., Inc., N.J. Superior Ct. (Atlantic County), Docket No. ATL-L-07319-06-MT, Case No. 619 ($65 million Vioxx settlement), In re Actiq Sales and Marketing Practices Litig., 790 F. Supp. 2d 313 (E.D. Pa. 2011), In re Pharmaceutical Industry Average Wholesale Price Litig., Case No. 01-CV-12257, MDL No.1456 (D. Mass.) (ISHP counsel for opt-out TPPs), Humana, Inc., et al. v. GlaxoSmithKline, Phila. C.C.P., December Term 2004, No. 3140 (Augmentin opt-out settlement), In re: Cardizem CD Antitrust Litig., 218 F.R.D. 508 (E.D. Mich. 2003) ($80 million settlement).
He represented Aetna in the recently resolved In re Neurontin Mktg. & Sales Practices Litig., 712 F.3d 51 (1st Cir. 2013) (holding drug manufacturers accountable to health insurers for damages attributable to marketing fraud), and currently as the representative of a certified class, in In re Wellbutrin XL Antitrust Litig., 282 F.R.D. 126 (E.D. Pa. 2011) and In re Wellbutrin XL Antitrust Litig., 756 F. Supp. 2d 670 (E.D. Pa. 2010) (the first decision to allow class action prosecution of antitrust claims under New York law).
Mr. Lawrence heads the firm’s mass tort lien recovery practice and prosecuted the following matters: In re Avandia Marketing Sales Practices and Products Liability Litigation, 685 F.3d 353 (3d Cir. 2012), cert. denied, 12-690, 2013 WL 1500235 (U.S. Apr. 15, 2013) and UnitedHealth Group, Inc. v. GlaxoSmithKline, LLC, Phila. C.C.P., Dec. Term, 2010, No. 2871 (Avandia state court proceeding), Avmed v. BrownGreer PLC, Case No. 08-30802 (E.D. La.) (Vioxx lien recovery litigation), Yaz Products Liability Litigation, including litigation pending in the United States District Court for the Southern District of Illinois (MDL 2100), the Philadelphia Court of Common Pleas, the N. J. Superior Court (Bergen County) and the Superior Court for the State of California, and the In re Hormone Therapy Products Liability Litig.
In the field of wage and hour litigation, he was class counsel and achieved settlements of $902,410 and $907,566 plus an agreement to change the company’s practices in Turner v. Best Buy Co. Inc., Case No. 08-cv-1024 (E.D.N.Y) and Hall v. Best Buy Co., Inc., 274 F.R.D. 154 (E.D. Pa. 2011); and also settled another suit against a national drugstore chain on behalf of a group of employees who were forced to perform off-the-clock work.
Mr. Lawrence has also represented defendants in winning dismissals of the following class action litigations: Meek-Horton v. Trover Solutions, 910 F. Supp. 2d 690 (2013); Potts v. Rawlings Co., LLC, 897 F. Supp. 2d 185 (2012); Kesselman v. The Rawlings Company, LLC, 668 F. Supp. 2d 604 (S.D.N.Y. 2009); Elliot Plaza Pharmacy v. Aetna U.S. Healthcare, 2009 WL 702837 (N.D. Okla. March 16, 2009); Main Drug, Inc. v. Aetna U.S. Healthcare, 475 F.3d 1228 (11th Cir. 2007) (dismissing appeals from Main Drug, Inc. v. Aetna U.S. Healthcare, 455 F. Supp. 2d 1323 (M.D. Ala. 2006) and 455 F. Supp. 2d 1317 (M.D. Ala. 2005); and is currently defending Aetna in the class action case: Roche, et al. v. Aetna, Inc., et al., Civ. 13-1377 (D.N.J.).
Prior to joining the firm, Mr. Lawrence directed plaintiff’s recovery work and commercial litigation efforts at Aetna, Inc. which caused U.S. District Judge Nancy Edmunds to recognize Mr. Lawrence as "a highly sophisticated representative" of the insurance industry. In re Cardizem CD Antitrust Litigation, 218 F.R.D. 508, 525, 535 (E.D. Mich. 2003).
Mr. Lawrence was given an AV rating by Martindale-Hubbell, the highest rating a lawyer can obtain, indicating a very high to preeminent legal ability and exceptional ethical standards as established by confidential opinions from members of the Bar. Mr. Lawrence is a graduate of Georgetown University (B.S.B.A. 1990) and the Villanova University School of Law (J.D. 1993). He is admitted to practice in Pennsylvania and New York; and in the U.S. Courts of Appeals for the 1st, 2nd and 3rd Circuits and the U.S. District Courts for the Eastern and Middle Districts of Pennsylvania and the Eastern and Southern Districts of New York.